FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W10347719> ?p ?o ?g. }

• W10347719 endingPage "1383" @default.
• W10347719 startingPage "1378" @default.
• W10347719 abstract "Purpose To describe a series of patients with secondary acute myelogenous leukemia (sAML) and retinoblastoma (RB). Design Retrospective observational cases series. Participants Ocular and pediatric oncologists at referral centers in Europe and the Americas and the RB databases at the National Institutes of Health and the Ophthalmic Oncology Service at Memorial Sloan-Kettering Cancer Center. Methods Physician survey, retrospective database review, and literature search. Main Outcome Measures History of RB and development of sAML, management of RB (surgery, radiotherapy, chemotherapy), age at diagnosis of RB and leukemia, French-American-British (FAB) subtype, and current status of patient (alive or dead). Results Fifteen patients with sAML were identified; 13 occurred in childhood. Mean latent period from RB to AML diagnosis was 9.8 years (median, 42 months). Nine cases were of the M2 or M5 FAB subtypes. Twelve patients (79 %) had received chemotherapy with a topoisomerase II inhibitor, 8 (43%) had received chemotherapy with an epipodophyllotoxin. Ten children died of their leukemia. Conclusions Acute myelogenous leukemia is a rare secondary malignancy among retinoblastoma patients, many of whom were treated with primary or adjuvant chemotherapy. Additional studies are needed to assess potential risk factors contributing to sAML development in this cohort. To describe a series of patients with secondary acute myelogenous leukemia (sAML) and retinoblastoma (RB). Retrospective observational cases series. Ocular and pediatric oncologists at referral centers in Europe and the Americas and the RB databases at the National Institutes of Health and the Ophthalmic Oncology Service at Memorial Sloan-Kettering Cancer Center. Physician survey, retrospective database review, and literature search. History of RB and development of sAML, management of RB (surgery, radiotherapy, chemotherapy), age at diagnosis of RB and leukemia, French-American-British (FAB) subtype, and current status of patient (alive or dead). Fifteen patients with sAML were identified; 13 occurred in childhood. Mean latent period from RB to AML diagnosis was 9.8 years (median, 42 months). Nine cases were of the M2 or M5 FAB subtypes. Twelve patients (79 %) had received chemotherapy with a topoisomerase II inhibitor, 8 (43%) had received chemotherapy with an epipodophyllotoxin. Ten children died of their leukemia. Acute myelogenous leukemia is a rare secondary malignancy among retinoblastoma patients, many of whom were treated with primary or adjuvant chemotherapy. Additional studies are needed to assess potential risk factors contributing to sAML development in this cohort." @default.
• W10347719 created "2016-06-24" @default.
• W10347719 creator A5005708135 @default.
• W10347719 creator A5025388138 @default.
• W10347719 creator A5025500380 @default.
• W10347719 creator A5029438789 @default.
• W10347719 creator A5032519145 @default.
• W10347719 creator A5040536765 @default.
• W10347719 creator A5047847872 @default.
• W10347719 creator A5052394396 @default.
• W10347719 creator A5054604607 @default.
• W10347719 creator A5057059839 @default.
• W10347719 creator A5061310711 @default.
• W10347719 creator A5062746651 @default.
• W10347719 creator A5068118481 @default.
• W10347719 creator A5072765562 @default.
• W10347719 creator A5074440136 @default.
• W10347719 creator A5078965109 @default.
• W10347719 creator A5087702757 @default.
• W10347719 date "2007-07-01" @default.
• W10347719 modified "2023-10-18" @default.
• W10347719 title "Secondary Acute Myelogenous Leukemia in Patients with Retinoblastoma" @default.
• W10347719 cites W1556555576 @default.
• W10347719 cites W1701536174 @default.
• W10347719 cites W1833467461 @default.
• W10347719 cites W1835336809 @default.
• W10347719 cites W1847176704 @default.
• W10347719 cites W1966444756 @default.
• W10347719 cites W1978953017 @default.
• W10347719 cites W1982797125 @default.
• W10347719 cites W1984183735 @default.
• W10347719 cites W2008988125 @default.
• W10347719 cites W2010349188 @default.
• W10347719 cites W2031454576 @default.
• W10347719 cites W2033309625 @default.
• W10347719 cites W2034247450 @default.
• W10347719 cites W2034960473 @default.
• W10347719 cites W2045388751 @default.
• W10347719 cites W2045862971 @default.
• W10347719 cites W2050380837 @default.
• W10347719 cites W2050459506 @default.
• W10347719 cites W2051197383 @default.
• W10347719 cites W2051404433 @default.
• W10347719 cites W2060658196 @default.
• W10347719 cites W2063450415 @default.
• W10347719 cites W2066923595 @default.
• W10347719 cites W2082876519 @default.
• W10347719 cites W2101105175 @default.
• W10347719 cites W2102455681 @default.
• W10347719 cites W2102706108 @default.
• W10347719 cites W2123528350 @default.
• W10347719 cites W2126964833 @default.
• W10347719 cites W2134294240 @default.
• W10347719 cites W2136400910 @default.
• W10347719 cites W2154962291 @default.
• W10347719 cites W2158843184 @default.
• W10347719 cites W2162201423 @default.
• W10347719 cites W2171300427 @default.
• W10347719 cites W2242925189 @default.
• W10347719 cites W2244637994 @default.
• W10347719 cites W2313420578 @default.
• W10347719 cites W2333611917 @default.
• W10347719 cites W4231078793 @default.
• W10347719 doi "https://doi.org/10.1016/j.ophtha.2007.03.074" @default.
• W10347719 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17613328" @default.
• W10347719 hasPublicationYear "2007" @default.
• W10347719 type Work @default.
• W10347719 sameAs 10347719 @default.
• W10347719 citedByCount "182" @default.
• W10347719 countsByYear W103477192012 @default.
• W10347719 countsByYear W103477192013 @default.
• W10347719 countsByYear W103477192014 @default.
• W10347719 countsByYear W103477192015 @default.
• W10347719 countsByYear W103477192016 @default.
• W10347719 countsByYear W103477192017 @default.
• W10347719 countsByYear W103477192018 @default.
• W10347719 countsByYear W103477192019 @default.
• W10347719 countsByYear W103477192020 @default.
• W10347719 countsByYear W103477192021 @default.
• W10347719 countsByYear W103477192022 @default.
• W10347719 countsByYear W103477192023 @default.
• W10347719 crossrefType "journal-article" @default.
• W10347719 hasAuthorship W10347719A5005708135 @default.
• W10347719 hasAuthorship W10347719A5025388138 @default.
• W10347719 hasAuthorship W10347719A5025500380 @default.
• W10347719 hasAuthorship W10347719A5029438789 @default.
• W10347719 hasAuthorship W10347719A5032519145 @default.
• W10347719 hasAuthorship W10347719A5040536765 @default.
• W10347719 hasAuthorship W10347719A5047847872 @default.
• W10347719 hasAuthorship W10347719A5052394396 @default.
• W10347719 hasAuthorship W10347719A5054604607 @default.
• W10347719 hasAuthorship W10347719A5057059839 @default.
• W10347719 hasAuthorship W10347719A5061310711 @default.
• W10347719 hasAuthorship W10347719A5062746651 @default.
• W10347719 hasAuthorship W10347719A5068118481 @default.
• W10347719 hasAuthorship W10347719A5072765562 @default.
• W10347719 hasAuthorship W10347719A5074440136 @default.
• W10347719 hasAuthorship W10347719A5078965109 @default.

• next